ORIC ORIC Pharmaceuticals Inc

518

$8.87

$0.42

(4.97%)

Today

Watchers	518
52-Wk Low	$2.91
52-Wk High	$9.79

Market Cap	$460.96M
Volume (M)	654,255.00
52-Wk High	$9.79
52-Wk Low	$2.91

Fundamentals

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Globe Newswire • 5 days ago

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 01, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that...

Share to Feed

Oric Pharmaceuticals (ORIC, $6.53) entered Downtrend as Momentum indicator drops below 0 level on Nov 15, 2023Tickeron - Stocks • 20 days ago

This indicator may be signaling that ORIC's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Oric Pharmaceuticals (ORIC, $6.43) entered Downtrend as Momentum indicator drops below 0 level on Nov 09, 2023Tickeron - Stocks • 26 days ago

ORIC Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobe Newswire • 27 days ago

SOUTH SAN FRANCISCO and SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...

ORIC Pharmaceuticals Inc (ORIC) Reports Q3 2023 Financial Results and Operational UpdatesGuruFocus • 30 days ago

ORIC's Cash and Investments Reach $256.2 Million, R&D Expenses Increase to $22.4 MillionRelated Stocks: ORIC...

Oric Pharmaceuticals reports Q3 EPS (44c), consensus (46c)The Fly • 30 days ago

See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational UpdatesGlobe Newswire • 30 days ago

Presented initial Phase 1b data for ORIC-114 in patients with EGFR and HER2 Exon 20 mutated NSCLC demonstrating potential best-in-class profile Initial Phase 1b data for ORIC-533 in patients with...

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Globe Newswire • about 1 month ago

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that...

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual MeetingGlobe Newswire • about 1 month ago

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...

Oric Pharmaceuticals (ORIC) Shares Cross Above 200 DMAMarket News Video • about 1 month ago

In trading on Thursday, shares of Oric Pharmaceuticals Inc (ORIC) crossed above their 200 day moving average of 6.34, changing hands as high as 7.04 per share. Oric Pharmaceuticals Inc...